DRUGS IN R&D

Scope & Guideline

Connecting researchers for a healthier tomorrow.

Introduction

Welcome to your portal for understanding DRUGS IN R&D, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1174-5886
PublisherSPRINGER INT PUBL AG
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Converge1999, from 2002 to 2008, from 2010 to 2024
AbbreviationDRUGS R&D / Drugs R&D
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressGEWERBESTRASSE 11, CHAM CH-6330, SWITZERLAND

Aims and Scopes

The journal 'DRUGS IN R&D' focuses on the evolving landscape of drug development and research, emphasizing clinical trials, pharmacokinetics, safety assessments, and novel therapeutic approaches. It serves as a platform for sharing significant findings that contribute to the enhancement of drug efficacy and patient care.
  1. Clinical Pharmacology and Drug Development:
    The journal emphasizes the study of pharmacokinetics and pharmacodynamics, exploring how drugs behave in the body and their effects on biological systems. This includes research on drug interactions, bioavailability, and the impact of various factors on drug metabolism.
  2. Therapeutic Innovation and Efficacy:
    It highlights innovative therapies, including novel drugs and repurposed medications, focusing on their therapeutic efficacy in treating various conditions. The journal covers a wide range of diseases, from oncology to infectious diseases, showcasing advances in treatment options.
  3. Patient-Centric Research:
    The importance of patient-reported outcomes and real-world evidence is underscored, reflecting a commitment to incorporating patient perspectives into drug development and clinical practice.
  4. Biosimilars and Drug Comparisons:
    A significant area of focus is the evaluation of biosimilars and their comparability to reference products, including studies on safety, efficacy, and pharmacological properties.
  5. Regulatory and Safety Assessments:
    The journal contributes to discussions on regulatory challenges and safety assessments in drug development, aiming to inform better practices in clinical trials and post-marketing surveillance.
The journal 'DRUGS IN R&D' has demonstrated a dynamic evolution in its research themes, with several emerging areas gaining traction in recent publications. These trends reflect current challenges in drug development and the need for innovative solutions.
  1. Precision Medicine and Pharmacogenomics:
    Recent papers highlight the role of pharmacogenomics in tailoring drug therapies to individual genetic profiles, indicating a growing interest in precision medicine approaches that enhance treatment efficacy and minimize adverse effects.
  2. Real-World Evidence and Outcomes Research:
    There is an increasing focus on real-world evidence, utilizing data from clinical practice to assess drug effectiveness and safety post-approval. This trend underscores the importance of understanding how treatments perform outside controlled clinical trial settings.
  3. Biosimilars and Comparative Effectiveness:
    With the rise of biosimilars, there is a noticeable trend towards comparative studies that evaluate their efficacy and safety against reference biologics, reflecting the market's shift towards cost-effective alternatives.
  4. Drug-Drug Interaction Studies:
    Research exploring complex drug-drug interactions, especially in vulnerable populations with comorbidities, is becoming more prevalent, highlighting the need for comprehensive safety profiles in polypharmacy scenarios.
  5. Innovative Drug Delivery Systems:
    Emerging studies are focusing on novel drug delivery mechanisms that enhance bioavailability and therapeutic outcomes, such as prolonged-release formulations and nanotechnology applications.

Declining or Waning

While 'DRUGS IN R&D' maintains a robust focus on various aspects of drug research, certain themes have shown a decline in prominence over the years. This shift may reflect changing priorities in the field or the maturation of previously emerging areas.
  1. Traditional Pharmacotherapy Studies:
    Research focusing solely on traditional pharmacotherapeutic approaches has seen a decrease, as there is a growing emphasis on personalized medicine and targeted therapies that consider individual patient variability.
  2. Basic Laboratory Research:
    Studies that primarily focus on preclinical laboratory findings without a direct translational aspect to clinical applications appear to be waning, indicating a trend towards more clinically relevant research.
  3. General Drug Safety Reports:
    There is a noticeable decline in the publication of broad safety reports that do not delve into specific drug interactions or patient populations, suggesting a shift towards more targeted safety assessments.

Similar Journals

CLINICAL PHARMACOKINETICS

Championing Innovations in Drug Delivery and Metabolism
Publisher: ADIS INT LTDISSN: 0312-5963Frequency: 12 issues/year

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

CARDIOVASCULAR DRUGS AND THERAPY

Advancing cardiovascular care through cutting-edge research.
Publisher: SPRINGERISSN: 0920-3206Frequency: 6 issues/year

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

CPT-Pharmacometrics & Systems Pharmacology

Exploring the future of drug development and patient safety.
Publisher: WILEYISSN: 2163-8306Frequency: 12 issues/year

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Empowering healthcare through cutting-edge pharmacological studies.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0946-1965Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Transforming Insights into Innovations
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Clinical Pharmacology-Advances and Applications

Bridging Research and Practice in Pharmacology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1438Frequency: 1 issue/year

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

INDIAN JOURNAL OF PHARMACOLOGY

Transforming clinical practices with groundbreaking pharmacological research.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Enhancing Veterinary Practices with High-Quality Scientific Insights
Publisher: WILEYISSN: 0140-7783Frequency: 6 issues/year

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.

Drug Research

Bridging Science and Medicine for Better Outcomes
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Clinical Pharmacology in Drug Development

Advancing pharmaceutical science for a healthier tomorrow.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.